tiprankstipranks
Trending News
More News >
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
US Market

TransCode Therapeutics (RNAZ) Income Statement

Compare
431 Followers

TransCode Therapeutics Income Statement

Last quarter (Q3 2025), TransCode Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, TransCode Therapeutics's net income was $-4.86M. See TransCode Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ -534.86K$ -516.75K$ -98.61K$ -42.47K$ 0.00
Operating Expenses
$ 15.13M$ 18.90M$ 18.57M$ 6.11M$ 726.60K
Depreciation and Amortization
$ 534.86K$ 516.75K$ 98.61K$ 42.47K$ 0.00
EBITDA
$ -16.19M$ -17.97M$ -17.47M$ -6.71M$ -1.95M
Operating Income
$ -15.66M$ -19.42M$ -18.67M$ -6.15M$ -726.60K
Other Income/Expenses
$ -1.09M$ 872.42K$ 1.10M$ -692.26K$ -1.62M
Pretax Income
$ -16.75M$ -18.55M$ -17.56M$ -6.84M$ -2.34M
Net Income
$ -16.75M$ -18.55M$ -17.56M$ -6.84M$ -2.34M
Per Share Metrics
Basic EPS
$ -47.14$ -3.45K$ -73.19K$ -648.00$ -293.76
Diluted EPS
$ -47.14$ -3.45K$ -1.08K$ -648.00$ -293.76
Weighted Average Shares Outstanding
356.12K- 16.22K 10.53K 7.98K
Weighted Average Shares Outstanding (Diluted)
356.12K- 16.22K 10.53K 7.98K
Currency in USD

TransCode Therapeutics Earnings and Revenue History